RWC Asset Management LLP Takes Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

RWC Asset Management LLP acquired a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 6,147 shares of the medical device company’s stock, valued at approximately $221,000.

A number of other hedge funds have also recently made changes to their positions in TNDM. Brooklyn Investment Group purchased a new stake in Tandem Diabetes Care during the third quarter valued at $28,000. Assetmark Inc. bought a new position in Tandem Diabetes Care during the 3rd quarter valued at about $29,000. McIlrath & Eck LLC purchased a new stake in Tandem Diabetes Care in the 3rd quarter worth about $52,000. Venturi Wealth Management LLC raised its holdings in shares of Tandem Diabetes Care by 5,955.9% in the fourth quarter. Venturi Wealth Management LLC now owns 2,059 shares of the medical device company’s stock worth $74,000 after buying an additional 2,025 shares during the period. Finally, Stonehage Fleming Financial Services Holdings Ltd bought a new stake in shares of Tandem Diabetes Care during the fourth quarter worth $92,000.

Wall Street Analyst Weigh In

TNDM has been the subject of a number of recent research reports. Robert W. Baird reduced their price objective on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating for the company in a research note on Thursday, November 7th. Canaccord Genuity Group dropped their price objective on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Sanford C. Bernstein assumed coverage on shares of Tandem Diabetes Care in a research report on Wednesday, November 6th. They set an “outperform” rating and a $42.00 target price for the company. Citigroup lowered their price target on shares of Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Finally, Barclays lifted their price objective on Tandem Diabetes Care from $58.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Tandem Diabetes Care has a consensus rating of “Moderate Buy” and a consensus price target of $53.81.

Tandem Diabetes Care Stock Down 3.5 %

Shares of TNDM stock opened at $31.00 on Monday. Tandem Diabetes Care, Inc. has a twelve month low of $24.42 and a twelve month high of $53.69. The company has a market capitalization of $2.04 billion, a price-to-earnings ratio of -16.06 and a beta of 1.32. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The stock’s 50 day simple moving average is $35.48 and its 200 day simple moving average is $36.70.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.